Follow The Filings

DMAC Diamedica Therapeutics Inc.

Health Care, filed as DIAMEDICA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.7%
  • $24M
  • 1 add

In 2026 Q2 Leon Cooperman added to Diamedica Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.7% (Leon Cooperman, Omega Advisors). Not free-float ownership.

  1. Leon Cooperman Add 0.68%

Who owns DMAC

Sorted by value, long equity only, as of 2026 Q2.

History
Leon Cooperman, Omega Advisors 0.68%, was 0.44% Add +70.8% 3,450,000 $24M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DMAC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DMAC insider trades
  • $7.6M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Jan Stahlberg 10% owner, +1 joint filer
    Buy
    $7.6M 1,061,277 shares at $7.19 +14% to stake
    Traded Nov 17–25 Filed Dec 8, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 4 stock grants and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
DEF 14A FORM DEF 14A Filing Doc
DEFA14A FORM DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
424B2 FORM 424B2 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 1.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$19.38M -$24.44M -$32.77M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $53.68M $44.61M $60.63M
Total non-current assets $0.485M $1.74M $0.742M
Total assets $54.16M $46.34M $61.37M
Total current liabilities $2.79M $5.39M $5.13M
Total non-current liabilities $317,000 $237,000 $128,000
Total equity $51.06M $40.72M $56.11M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$18.73M -$22.08M -$29.06M
Cash from investing -$18.3M $8.56M -$2.19M
Cash from financing $36.84M $11.99M $43.88M
Net change in cash -$0.185M -$1.52M $12.62M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.